rs6445975 — PXK

PXK — The Endosomal Gatekeeper Implicated in Lupus Susceptibility

PXK¹¹ PXK
PX domain containing serine/threonine kinase like; a protein containing a phox homology (PX) domain that binds phosphoinositide lipids on endosomal membranes, positioning it in the trafficking machinery that sorts internalized receptors for recycling or degradation is a gene most people have never heard of — yet a variant within its intron has appeared consistently in genome-wide association scans for systemic lupus erythematosus (SLE) in European populations. The rs6445975 G allele was one of four loci with genome-wide significant replication in the landmark 2008 SLEGEN consortium study, placing PXK alongside more familiar SLE genes like ITGAM and STAT4. What makes PXK biologically interesting is its proposed role in controlling how immune cells terminate signalling after receptor engagement — a cellular housekeeping function with outsized consequences when disrupted in autoimmune contexts.

The Mechanism

PXK's PX domain binds phosphatidylinositol 3-phosphate (PtdIns3P)²² phosphatidylinositol 3-phosphate (PtdIns3P)
A phospholipid lipid enriched on the cytoplasmic face of early endosomes; serves as a docking signal for proteins involved in vesicle trafficking, autophagy, and receptor sorting, the signature lipid of early endosomes. This positions PXK in the endosomal sorting machinery — the cellular system that decides, after a surface receptor is internalized, whether it is recycled back to the cell surface or directed to the lysosome for degradation. Epidermal growth factor receptor (EGFR) was identified as one cargo whose degradation is regulated by proteins in the PtdIns3P-binding family that includes PXK, based on siRNA screening data.

The immune relevance is that B-cell receptor (BCR) internalization follows a mechanistically similar endosomal sorting pathway. When the BCR binds antigen, it is rapidly internalized and trafficked through endosomes for antigen processing and presentation. The efficiency of this internalization — and therefore the strength and duration of the resulting immune activation — is regulated by the same PtdIns3P-dependent endosomal machinery in which PXK participates. Reduced or altered PXK function could impair the timely termination of BCR signalling, allowing prolonged immune activation. In lupus, where B cells are already hyperactivated and produce pathogenic autoantibodies, any genetic variant that prolongs BCR signalling is a plausible contributor to disease susceptibility.

rs6445975 sits in an intron of PXK, suggesting it acts as a regulatory variant — altering expression levels or splicing of PXK isoforms in specific immune cell types rather than changing the protein sequence directly. The exact functional consequence at the molecular level has not been characterised in published eQTL studies, making the mechanistic link to BCR trafficking inferential rather than directly demonstrated.

The Evidence

The variant was first identified in the landmark 2008 SLEGEN genome-wide scan³³ landmark 2008 SLEGEN genome-wide scan led by Harley and colleagues, which examined 720 women with SLE plus 2,337 controls in the discovery cohort, with replication in a further 1,846 cases and 1,825 controls. PXK (along with ITGAM, KIAA1542, and other loci) showed evidence of association with replication across the study cohorts.

The most precise quantification comes from a 2012 meta-analysis by Lee et al.⁴⁴ 2012 meta-analysis by Lee et al. synthesising 13 studies: the rs6445975 G allele was associated with SLE at OR 1.151 (95% CI 1.086–1.291, p=1.8×10⁻⁶) in the overall population, with a stronger signal in European subgroups (OR 1.198, 95% CI 1.118–1.285, p=3.4×10⁻⁷). Notably, the Asian subgroup showed no significant association — a finding replicated independently⁵⁵ replicated independently in 910 Hong Kong Chinese SLE patients (OR 1.06, p=0.36) and Korean patients⁶⁶ Korean patients (OR 1.06, p=0.57). This population specificity is consistent with different linkage disequilibrium⁷⁷ linkage disequilibrium
The non-random association of alleles at two or more loci; a tagging SNP may associate strongly with a causal variant in one population but not another if LD patterns differ across ancestries (LD) structure around the locus across ancestries.

The strongest per-genotype effect sizes come from a 2022 Iranian case-control study⁸⁸ 2022 Iranian case-control study (110 SLE patients, 115 controls): GG homozygotes showed an OR of 7.5 versus TT (95% CI 3.47–17.07), and G allele carriers overall had a 3.55-fold elevated risk. The G allele also correlated with elevated inflammatory markers (CRP, ESR), anti-dsDNA antibody levels, complement consumption (C3/C4 abnormalities), renal involvement, and skin lesions. A Chinese cohort study⁹⁹ Chinese cohort study reinforced the autoantibody connection even in a population where overall SLE risk was not significantly elevated: the G allele was significantly associated with anti-Smith (OR 1.95), anti-Ro (OR 1.69), and anti-La (OR 1.86) antibodies — suggesting that PXK influences the specificity and breadth of autoantibody production independently of overall disease susceptibility.

The evidence level is moderate: the association is consistently replicated in European populations across multiple independent cohorts and a meta-analysis, the OR per allele (~1.15–1.2) is modest but statistically robust, and the biological mechanism (endosomal receptor trafficking) is plausible. However, the causal variant has not been identified, eQTL studies have not definitively linked rs6445975 to PXK expression, and the Asian non-replication raises questions about whether rs6445975 is the causal variant or a tagging SNP in partial LD with the functional locus.

Practical Implications

For G allele carriers — particularly those of European ancestry — the practical implications focus on early detection and proactive monitoring for early lupus features, rather than on any specific nutrient or supplement intervention. SLE is an episodic, multi-system disease whose early signs (photosensitivity, butterfly rash, joint pain, unexplained fatigue, serositis) are often attributed to other causes for years before diagnosis. The OR of ~1.15–1.2 per G allele is modest in isolation, but GG homozygotes appear to carry a substantially higher burden in Middle Eastern cohorts. Any G allele carrier with a first-degree relative with lupus, or with recurrent unexplained symptoms across multiple organ systems, has grounds to request early ANA (antinuclear antibody) screening.

Hydroxychloroquine is the cornerstone treatment for SLE and has been shown to reduce disease flares, prevent organ damage, and improve survival. Carriers of elevated-risk genotypes who are diagnosed with SLE or an undifferentiated connective tissue disease should be aware that early initiation of hydroxychloroquine is recommended by ACR/EULAR guidelines.

Interactions

The PXK locus exists within a broader landscape of SLE genetic susceptibility. STAT4 (rs7574865)¹⁰¹⁰ STAT4 (rs7574865) is one of the most strongly replicated SLE risk loci (OR ~1.5–1.7), acting through interferon-γ signalling in T cells. PTPN22 (rs2476601)¹¹¹¹ PTPN22 (rs2476601) is a well-established autoimmune risk variant disrupting T-cell and B-cell receptor signalling thresholds, also in the GeneOps database. BLK (rs13277113)¹²¹² BLK (rs13277113) encodes a B-lymphocyte kinase directly involved in BCR signalling — the same pathway that PXK's endosomal role putatively modulates. Carrying multiple SLE risk alleles across STAT4, BLK, PTPN22, and PXK represents an additive polygenic risk burden significantly exceeding any single locus. No specific compound action has been formally documented for PXK + BLK, but the biological logic of convergent BCR-pathway disruption is strong.